UK-based gynaecological health startup Daye, which is known for having invented the CBD tampon that is now used by over 60,000 women in the UK, has raised a £10M Series A from London-based Hambro Perks. Other participants in the round also include MassMutual Ventures, Cross Border Impact Ventures as well as leading UK health solutions provider, Simplyhealth, who will collaborate with Daye…
Bayer Malaysia has teamed up with the MyEndosis, the Endometriosis Association of Malaysia and DoctorOnCall, a digital health platform by Health Digital Technologies, to launch a new telehealth platform dedicated to endometriosis. The new service will provide online consultations with OB/GYNs from DoctorOnCall, which will be free of charge for a three-month period starting this June. Bayer’s Country Division head for Singapore, Malaysia…
ObsEva has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective as of market open on Monday, December 20, 2021. The biotech company develops and commercializes novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on new therapies for the treatment…
Gynecological imaging startup Illumigyn has raised $33M from investors including Yozma Group Korea and Ubicom Holdings Japan to fund its global expansion. The company’s vision is to disrupt the medical field of gynecology with a complete platform solution featuring the Gynescope System, a new and FDA cleared “gynecology endoscope” and cloud platform service. Illumigyn was founded in Israel by Ran Poliakine and…
Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, has received FDA clearance for Sonata System 2.2, which provides new benefits for facilities, physicians and patients. These benefits include a 20% reduction in the smallest ablation size setting, which greatly increases the ability to treat fibroids in tighter anatomical locations, new software advances that…
Hologic’s Acessa procedure is now covered by Anthem Blue Cross Blue Shield, the second largest health plan in the United States. Anthem has updated its medical policy to cover Radiofrequency Ablation (LAP-RFA), which includes the Acessa procedure for women suffering from uterine fibroids. The updated policy creates access to uterine-preserving care for Anthem’s approximately 40 million members in all 50 states, providing…
AOA Dx has signed an Exclusive License Agreement with Professor H. Uri Saragovi, a Senior Investigator with the Lady Davis Institute at the Jewish General Hospital and Professor at McGill University, to secure a suite of IP related to utilizing gangliosides for early cancer detection through liquid biopsies. A family of gangliosides function as tumor markers, as they are low or absent…
Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that Cigna has released a national coverage policy for treatment of uterine fibroids with the Sonata System. The Sonata System uses radiofrequency energy to ablate fibroids under real time sonography guidance from within the uterine cavity, utilizing the first and only intrauterine ultrasound…
